News
UNCY
7.13
-13.15%
-1.08
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Unicycive Therapeutics (UNCY)
TipRanks · 1d ago
H.C. Wainwright recommends taking advantage of Unicycive stock weakness
TipRanks · 1d ago
Unicycive seeks to distinguish OLC in crowded CKD hyperphosphatemia market
Seeking Alpha · 6d ago
Unicycive Therapeutics shareholders ratified Grassi & Co. as auditor for fiscal 2026
PUBT · 6d ago
Weekly Report: what happened at UNCY last week (0615-0619)?
Weekly Report · 6d ago
Weekly Report: what happened at UNCY last week (0608-0612)?
Weekly Report · 06/15 09:40
These healthcare stocks are combining strong gains with reasonable prices
Seeking Alpha · 06/12 10:38
Stock Picks From Seeking Alpha's May 2026 New Analysts
Seeking Alpha · 06/08 13:00
Weekly Report: what happened at UNCY last week (0601-0605)?
Weekly Report · 06/08 09:37
Unicycive Expands At-The-Market Equity Offering Program
TipRanks · 06/05 21:46
Unicycive Therapeutics files $150M mixed securities shelf
TipRanks · 06/05 20:20
Unicycive Therapeutics Files Base Prospectus For Offering Up To $150M Securities
Benzinga · 06/05 20:19
UNICYCIVE THERAPEUTICS - FILES SALES AGREEMENT PROSPECTUS TO OFFER UP TO $50 MLN OF COMMON STOCK - SEC FILING
Reuters · 06/05 20:17
Unicycive publishes corporate presentation on OLC hyperphosphatemia treatment for dialysis patients
PUBT · 06/04 21:16
Unicycive Therapeutics Is Maintained at Speculative Buy by Benchmark
Dow Jones · 06/02 15:11
Unicycive Therapeutics Price Target Raised to $18.00/Share From $15.00 by Benchmark
Dow Jones · 06/02 15:11
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $18
Benzinga · 06/02 15:00
Unicycive Therapeutics price target raised to $18 from $15 at Benchmark
TipRanks · 06/02 13:07
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Unicycive Therapeutics (UNCY)
TipRanks · 06/02 07:50
Weekly Report: what happened at UNCY last week (0525-0529)?
Weekly Report · 06/01 09:40
More
Webull provides a variety of real-time UNCY stock news. You can receive the latest news about Unicycive Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.